GuidelinePloS one2022
The Australian living guidelines for the clinical care of people with COVID-19: What worked, what didn't and why, a mixed methods process evaluation.
Guideline in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Addressing evidence needs during health crises in the province of Quebec (Canada): a proposed action plan for rapid evidence synthesis.BMC health services research · 2025Article
- Examining self-described policy-relevant evidence base for policymaking: an evidence map of COVID-19 literature.BMJ public health · 2024Article
- A living critical interpretive synthesis to yield a framework on the production and dissemination of living evidence syntheses for decision-making.Implementation science : IS · 2024Review
- Living methods for living guidelines: Changes to evidence synthesis methods in the Australian National Clinical Evidence Taskforce COVID-19 living guidelines.Clinical and public health guidelines · 2024Article
- Designing, refining and reflecting on 3 years of daily evidence surveillance for Australia's living national COVID-19 guidelines.Cochrane evidence synthesis and methods · 2024Article
- Barriers to and facilitators of living guidelines use in low-income and middle-income countries: a scoping review.BMJ open · 2024Article
- Living Systematic Reviews and Living Guidelines to Maintain the Currency of Public Health Guidelines.American journal of public health · 2024Article
- Weekly updating of guideline recommendations was feasible: the Australian National COVID-19 clinical evidence Taskforce.Journal of clinical epidemiology · 2023Article
- Awareness, value and use of the Australian living guidelines for the clinical care of people with COVID-19: an impact evaluation.Journal of clinical epidemiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe Australian National COVID-19 Clinical Evidence Taskforce is producing living, evidence-based, national guidelines for treatment of people with COVID-19 which are updated each week. To continually improve the process and outputs of the Taskforce, and inform future living guideline development, we undertook a concurrent process evaluation examining Taskforce activities and experience of team members and stakeholders during the first 5 months of the project.
methodsThe mixed-methods process evaluation consisted of activity and progress audits, an online survey of all Taskforce participants; and semi-structured interviews with key contributors. Data were collected through five, prospective 4-weekly timepoints (beginning first week of May 2020) and three, fortnightly retrospective timepoints (March 23, April 6 and 20). We collected and analysed quantitative and qualitative data.
resultsAn updated version of the guidelines was successfully published every week during the process evaluation. The Taskforce formed in March 2020, with a nominal start date of March 23. The first version of the guideline was published two weeks later and included 10 recommendations. By August 24, in the final round of the process evaluation, the team of 11 staff, working with seven guideline panels and over 200 health decision-makers, had developed 66 recommendations addressing 58 topics. The Taskforce website had received over 200,000 page views. Satisfaction with the work of the Taskforce remained very high (>90% extremely or somewhat satisfied) throughout. Several key strengths, challenges and methods questions for the work of the Taskforce were identified.
conclusionsIn just over 5 months of activity, the National COVID-19 Clinical Evidence Taskforce published 20 weekly updates to the evidence-based national treatment guidelines for COVID-19. This process evaluation identified several factors that enabled this achievement (e.g. an extant skill base in evidence review and convening), along with challenges that needed to be overcome (e.g. managing workloads, structure and governance) and methods questions (pace of updating, and thresholds for inclusion of evidence) which may be useful considerations for other living guidelines projects. An impact evaluation is also being conducted separately to examine awareness, acceptance and use of the guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.